Back to 
BlackRock Finance, Inc.
BlackRock Finance, Inc.
LCTXShowing 0 of 3 quarters
Position history for BlackRock Finance, Inc.'s holdings in LINEAGE CELL THERAPEUTICS IN
As of its last 13F, for Q2 2024, BlackRock Finance held 9,559,466 shares of LCTX (Lineage Cell Therapeutics in), worth $9.5M. It increased the position by 1,065,071 shares (+12.5%) from Q1 2024. BlackRock Finance held LCTX from Q4 2023 to Q2 2024, across 3 quarterly 13F filings.
Current Value
-
Current Shares
-
Total Value Change
$0
Total Shares Change
0
No position history available for this security.
Other major holders of LCTX: BlackRock, Inc., VANGUARD GROUP INC, STATE STREET CORP, VANGUARD CAPITAL MANAGEMENT LLC